During a Senate committee hearing, Health Secretary Robert F. Kennedy Jr. announced a request for the FDA to review mifepristone, after a new study revealed that more than 10% of women face serious health risks post-ingestion, significantly higher than the FDA's reported 0.5%. This review, viewed positively by pro-life advocates, raises concerns over abortion access and women's safety. Kennedy's actions reflect a broader political push to reassess abortion medication regulations, with critics warning of potential dangers stemming from politicizing medical decisions.